P02-375 - Paliperidone augmentation for refractory obsessive-compulsive disorder: A case report - 05/05/11
Résumé |
Introduction |
Despite the substantial clinical improvements provided by the pharmacologic and cognitive-behavior therapies of OCD, it has been estimated that 40%–60% of patients still remains refractory to conventional treatment.
Objectives |
Medication augmentation can be an effective and well-tolerated short-term treatment strategy for non-responders to first-line pharmacotherapy of obsessive-compulsive disorders.
Aims |
To investigate the efficacy of paliperidone as augmenting agent in the treatment of resistant OCD patient.
Methods |
In the present case, we present a 6 months follow-up of an obsessive-compulsive patient treated with paliperidone ER and fluvoxamine. Paliperidone ER was started at 6mg/day and increased up to a maximum of 12mg/day. The clinical symptoms were measured by Y-BOCS and efficacy measures with CGI and PSP scale scores.
Results |
We found that obsessive-compulsive symptoms improved after 4weeks. Patient showed a significant improvement over the 6 months follow-up for Yale-Brown Obsessive Compulsive Scale total score at week 24 as compared with baseline (from a score of 34 to a score of 12). A significant improvement in the mean PSP scale score was also seen and “much improved” on the CGI score from baseline to end point. A mean bodyweight change of ≤2kg over the 24-week study period observed, but there were no clinically meaningful changes in glucose, insulin and blood lipid levels. There was no adverse event reported after the augmentation with paliperidone.
Conclusions |
Adding paliperidone to SSRIs could be a valid strategy for treatment-resistant OCD patients and additional efficacy studies and randomized, double-blind studies are needed.
Le texte complet de cet article est disponible en PDF.Vol 26 - N° S1
P. 971 - 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?